Navigation Links
A new agent for the treatment of patients with myelodysplastic syndrome; and more
Date:2/11/2008

A new agent for the treatment of patients with myelodysplastic syndrome

In a paper published this week in PLoS Medicine, Azra Raza and colleagues (University of Massachusetts) use gene expression profiling to identify a molecular signature that predicts response to lenalidomide in patients without chromosome 5q deletions. This suggests that these patients have a defect in erythroid differentiation.

In a related review article, Jerry Radich (Fred Hutchinson Cancer Research Center, Seattle, USA) reviews key research on the biology underlying treatment response in myelodysplasia, including Raza and colleagues' new study.

Citation: Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, et al. (2008) An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 5(2): e35.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050035

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-raza.pdf

CONTACT:

Azra Raza
University of Massachusetts
Division of Hematology Oncology
Worcester, MA 01605
United States of America
araza@aptiumoncology.com


Related PLoS Medicine perspective article:

Citation: Radich J (2008) Solving the mystery of myelodysplasia. PLoS Med 5(2): e40

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050040

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-radich.pdf

CONTACT:

Jerry Radich
Fred Hutchinson Cancer Research Center
Clinical Research Division
Seattle, Washington
United States of America
+1 206-667-4118
jradich@fhcrc.org


FROM THE PLoS MEDICINE MAGAZINE SECTION:

Salivating for knowledge: potential pharmacological agents in tick saliva

Joppe Hovius (University of Amsterdam) and colleagues review anticoagulant and immunosuppressive proteins present in tick saliva, and discuss how immunologically targeting such molecules could prevent transmission of tick-borne pathogens.

Citation: Hovius JWR, Levi M, Fikrig E (2008) Salivating for knowledge: Potential pharmacological agents in tick saliva. PLoS Med 5(2): e43.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE

VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050043

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-05-02-hovius.pdf

CONTACT:

Joppe Hovius
University of Amsterdam, AMC
Center for Experimental and Molecular Medicine
Meibergdreef 9
Amsterdam, Noord-Holland 1105 AZ
Netherlands
+31205666034
+31206977192 (fax)
j.w.hovius@amc.uva.nl


'/>"/>

Contact: Josh Eveleth
jeveleth@plos.org
415-624-1234
Public Library of Science
Source:Eurekalert

Related medicine news :

1. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
2. ABR-Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio, Texas
3. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
4. Insurance Agents Call for State Senate to Improve Californias Health Care Reform Compromise
5. Allergic reactions to gadolinium-based contrast agents are rare, study finds
6. Make 2008 the Year to Find an Insurance Agent Thats Right for You
7. Agent orange chemical, dioxin, attacks the mitochondria to cause cancer, says Penn research team
8. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
9. Germ-Fighting Inhaler Could Fend Off Bioterror Agents
10. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)
11. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... excited to announce the next generation for LASIK in Manhattan with Contoura Vision, ... most technologically advanced laser systems available in the United States to correct nearsightedness ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Community”: a gripping look at the religious stand in the sensitive matter ... love and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to ...
(Date:9/25/2017)... ... ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the New ... with the new NEXTY Gold Award at the Natural Products Expo East trade show ... is reserved for just those companies that hit high marks on the criteria of ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
(Date:9/24/2017)... Michigan (PRWEB) , ... September 23, 2017 , ... Throughout ... do no harm. , Every day, physicians, nurses and other providers work to ... treatments and innovative industry processes. , But U.S. Senators today are threatening to ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
Breaking Medicine Technology: